• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    UiPath (PATH) Gets A Healthcare AI Test Following Google Cloud Gemini Tie Up

    Simply Wall St·11/12/2026 20:21:42
    Listen to the news

    UiPath (PATH) just moved deeper into healthcare, announcing it is a launch partner for Google Cloud’s Gemini for healthcare. The fresh link between Gemini and UiPath’s automation platform gives investors a new product angle to track.

    Recent trading tells a different story to the product news flow. UiPath’s 1-day share price return of 2.42% comes after the stock declined 21.22% over 90 days and total shareholder return fell 29.62% over three years. This suggests enthusiasm is still rebuilding despite the Google Cloud Gemini headline.

    Scan how UiPath fits into the broader automation and AI trend by comparing it with hand picked 86 robotics and automation stocks shaping high stakes workflows in sectors like healthcare and finance.

    UiPath now pairs a fresh AI partnership with a stock that has already shed a lot of optimism. The key tension is simple: Is most of the rerating already in the rear view mirror, or is meaningful upside still ahead once valuation is unpacked next?

    Most Popular Narrative: 39% Undervalued

    UiPath closed at $13.14 while the most followed narrative on Simply Wall St puts fair value at $21.54. According to QuanD, an investor in the Simply Wall St Community, that gap reflects an AI opportunity that is real but not limitless.

    My original thesis for UiPath was that it could become one of the major beneficiaries of the second phase of the AI boom, where AI moves beyond generating answers and starts actually doing work. That thesis hasn’t disappeared. UiPath continues to build out its agentic automation platform, combining AI agents with its existing automation and orchestration capabilities.

    See why 45 investors see UiPath as 39% undervalued.

    The narrative uses a discount rate of 8.47% and assumes 10% annual revenue growth and a 20% profit margin, which leads to that $21.54 fair value mark, about 39% above the current share price. Under that framework, much of the upside case rests on UiPath sustaining double digit expansion while converting more of its $1.72b in revenue into lasting earnings, rather than a sharp reacceleration in top line growth.

    For readers weighing this against the recent share price slide and the Google Cloud Gemini launch, the key question is whether those narrative assumptions still feel comfortable when set against forecast earnings growth of 5.8% per year and revenue growth of 7.8% per year. The current DCF view from Simply Wall St points in the same direction, with UiPath trading 46.4% below an estimated future cash flow value of $24.53, so both lenses frame the stock as undervalued at today’s $13.14 level.

    Result: Fair Value of $21.54 (UNDERVALUED)

    Still, the UiPath narrative can break if large platforms bundle rival automation into existing suites, or if agentic tools take longer to translate into meaningful demand.

    Find out about the key risks to this UiPath narrative.

    Next Steps

    Mixed signals or a clear story forming for UiPath in your view? Act quickly on your curiosity by weighing both sides through the 4 key rewards and 1 important warning sign.

    Looking for more UiPath investment ideas?

    If UiPath has your attention but you want a wider bench of opportunities, do not stop here. A few targeted screens can quickly surface fresh ideas that fit your style.